Welcome to our dedicated page for Cibus news (Ticker: $CBUS), a resource for investors and traders seeking the latest updates and insights on Cibus stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cibus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cibus's position in the market.
Cibus (Nasdaq: CBUS), a leader in agricultural biotechnology, commends the Canadian Food Inspection Agency (CFIA) for updating its feed guidelines to regulate plants developed using gene editing, similar to conventional breeding. The guideline revision is part of a global trend, including the UK and EU, recognizing gene editing technologies like Cibus' RTDS® as safe and equivalent to traditional breeding methods. Cibus' RTDS platform aims to enhance global food productivity and sustainability. These guidelines are important for innovation and investment in Canada's agri-food sector, particularly for crops like canola. Cibus is progressing towards commercializing its Pod Shatter Reduction trait in canola, promising yield protection for Canadian farmers.
Cibus, Inc. (Nasdaq: CBUS) will participate in the BMO Global Farm to Market Conference with a presentation hosted by the CEO and COO on May 16, 2024. The company utilizes gene editing technologies to enhance plant traits in seeds.
Cibus, Inc. (Nasdaq: CBUS) reported Q1 2024 financial results and business update. Key highlights include success in single cell regeneration platform for Wheat, agreements in Rice, advancing Pod Shatter Reduction trait in Canola, and recognition by Fast Company. The PR also mentions global approval momentum for new genomic techniques, regulatory shifts in EU, and appointment of a new Chief Legal Officer, Jason Stokes. Financially, the company reported a cash position of $24.5 million, increased R&D and SG&A expenses, and a net loss of $27.0 million.
